Clinical Trials Logo

Thyroid Neoplasms clinical trials

View clinical trials related to Thyroid Neoplasms.

Filter by:

NCT ID: NCT04396912 Recruiting - Thyroid Cancer Clinical Trials

Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort

Start date: May 15, 2020
Phase:
Study type: Observational

In the present study, the severity of recurrent laryngeal nerve injury (RLNI) and hypocalcemia (H) will be followed-up and the probable interrelation between them will be proposed considering the clinical situation of patients, e.g. improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?), return of voice is parallel with the improvement in hypocalcemia? Postoperative calcium (Ca), parathyroid hormone (PTH), regular vocal cord evaluations by ear-nose-throat (ENT) exams, deterioration-stability-improvement of clinical symptoms regarding both Ca metabolism and vocal cord function will be noted at regular intervals (postoperative day 1-3-first, weekly control/first month, monthly/first 6-month, 3-monthly/6-12 months) at outpatient controls. Serum Ca, PTH, ENT evaluation of vocal cords-noted.

NCT ID: NCT04396158 Not yet recruiting - Radiation Exposure Clinical Trials

Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated. For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration. This study aimed to evaluate the effects of RAI therapy on ovarian function.

NCT ID: NCT04391244 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Investigating National Solutions for Personalised Iodine-131 Radiation Exposure

INSPIRE
Start date: June 17, 2020
Phase:
Study type: Observational

This is a single-arm non-interventional prospective observational study to perform quantitative I-131 imaging and patient-specific dosimetry for patients undergoing radioiodine treatment.

NCT ID: NCT04376203 Not yet recruiting - Microbiome Clinical Trials

Microbiome and Papillary Thyroid Microcarcinoma

Start date: July 27, 2020
Phase:
Study type: Observational

It has been shown that gut microbiome and microbiome metabolism can regulate or control the initiation of a cancer process. To the best of the investigators knowledge, no study has directly shown the relationship of the thyroid microcarcinoma to the human microbiome. In this work, the aim is to detect the microbiome in peripheral blood in a patient with a thyroid gland carcinoma, and to correlate it with the disease, compared to the microbiome of a group of patients who did not find another thyroid gland carcinoma

NCT ID: NCT04354324 Recruiting - Clinical trials for Papillary Thyroid Cancer

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

Start date: April 20, 2020
Phase: N/A
Study type: Interventional

Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi). Secondary objective: The successful remnant ablation, efficacy, 3-year progression-free survival and safety were compared between low-dose group (30 mCi) and high-dose group (100 mCi). Research Hypothesis:The 3-year disease-free survival of low-dose group (30mci) may not be lower than that of high-dose group (100 mci) in intermediate-risk thyroid papillary carcinoma patients with no structural or functional lesions and stimulated thyroglobulin(ps-Tg)1-20ng/ml. Study design:Single-center, randomized, double-blinded Sample size:254 patients Follow-up:The measurement of serum thyroid function, thyroglobulin/ anti-thyroglobulin antibody(Tg/TgAb) and neck ultrasonography were performed every 3-12 months during the 3 years according to patients' condition, and computerized tomography(CT) scan, positron emission tomography/computed tomography(PET/CT) and diagnostic whole-body 131I scan were added if necessary. Intervention:Randomly allocated into two groups to receive either 30 mCi (low-dose group) or 100 mCi (high-dose group ) radioiodine for post-thyroidectomy ablation therapy. Evaluation index:Primary evaluation index: The 3-year disease-free survival. Secondary evaluation index: Successful remnant ablation, efficacy, the 3-year progression-free survival and safety.

NCT ID: NCT04339478 Recruiting - Thyroid Cancer Clinical Trials

Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection

FLUOBCC
Start date: April 6, 2020
Phase:
Study type: Observational

The aim of the study is to evaluate the effectiveness of autofluorescence in the intraoperative preservation of parathyroids during total thyroidectomy with central lymph node compartment dissection.

NCT ID: NCT04336696 Recruiting - Clinical trials for Papillary Thyroid Carcinoma

Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?

Start date: November 2, 2016
Phase: N/A
Study type: Interventional

study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection. Recurrence Free Survival (RFS) was the main issue of the study and calculated as the time from date of surgery to date of relapse or the most recent follow-up contact that patient was known as relapse-free, Study exclusively studied the outcome and advantage of central neck dissection

NCT ID: NCT04327999 Terminated - Thyroid Carcinoma Clinical Trials

Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System

Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore whether administration of preservative free artificial tears will decrease the level of detectable radioiodine in the tears and nasolacrimal duct system of patients undergoing radioiodine therapy for thyroid carcinoma and thus decrease the risk of developing radioactive iodine associated nasolacrimal duct obstruction.

NCT ID: NCT04321954 Recruiting - Advanced Cancer Clinical Trials

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Start date: March 9, 2021
Phase: Phase 2
Study type: Interventional

This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib

NCT ID: NCT04320901 Recruiting - Thyroid Cancer Clinical Trials

Energy Device Study in Transoral Endoscopic Thyroidectomy

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

Open label randomized controlled study, for Harmonic versus Ligasure in transoral endoscopic thyroid surgery.